Pharmaceutical manufacturing decisions are made long before a patient ever sees a doctor. These decisions play a large role in a patient’s health. For a manufacturer, it can mean the difference between a timely active pharmaceutical ingredient (API) and the inability to make a product. For a patient, it may mean the difference between getting treatment and not getting any.
When something goes wrong with one of those decisions, it is rare for the problem to remain in the confines of the company. Patients notice right away. A prescription may arrive late, or a patient may need to change a treatment plan halfway through it. Unfortunately, very few people realize this.
Patients suffering from chronic diseases are affected most of all from the medication shortages:
Antidepressants: Doctors usually say that patients can suffer from withdrawals after 1-2 weeks without antidepressants.
Antipsychotics: Moreover, some patients may experience the symptoms of psychosis.
Though medication shortage may happen very often, it is not that common for people to realize that the shortage prolongs the wait for the patient.
That is why modern companies regard the choice of a pharmaceutical manufacturing partner as a critical decision. A good partner must ensure backup in case the problem occurs.
According to the FDA, manufacturing issues are indeed the main reason behind drug shortages. A single quality issue may affect several months of production plan.
Signs seen in the pharmaceutical sector indicate that there is a chronic problem with production capacities:
Having recorded and validated every stage of the process allows us to identify deviations.
The importance of identifying deviations cannot be overestimated since even the slightest alteration in the course of drug manufacturing can cause changes in the product. The partners that have many years of experience cooperate with regulators in various markets and know how to deal with inspections.
Moreover, a competent partner has acquired a network of facilities all round the globe. This provides a reliable base of flexible manufacturing partners that significantly reduces the chances of the occurrence of any failure.
Patients rarely see all this process. However, it contributes greatly to their treatment outcomes. An uninterrupted supply of pipeline drugs assures timely treatment provision. It is especially important for patients suffering from chronic and psychological disorders as this results in better treatment results.
As the processes in this specialization develop further on, specialization in production resources will be of utmost importance due to its scarcity of replacement as well.
Why Do Manufacturing Gaps Put Patients at Risk
The efficacy of any medication in a pharmacy is dependent on smooth operations of drug manufacturing. When there is any problem with the manufacturing process, even a small flaw leads to serious consequences. For example, a single production glitch can ruin an entire lot, which results in almost instantaneous depletion of drugs available in drugstores if the lot consists of a large amount of one drug. In this case, doctors have limited options.Patients suffering from chronic diseases are affected most of all from the medication shortages:
Antidepressants: Doctors usually say that patients can suffer from withdrawals after 1-2 weeks without antidepressants.
Antipsychotics: Moreover, some patients may experience the symptoms of psychosis.
Though medication shortage may happen very often, it is not that common for people to realize that the shortage prolongs the wait for the patient.
That is why modern companies regard the choice of a pharmaceutical manufacturing partner as a critical decision. A good partner must ensure backup in case the problem occurs.
What Do Shortage Trends Reveal About Pharmaceutical Manufacturing Gaps
At a national level, the issue of shortages can be seen in the statistics. By the midpoint of 2024, more than one hundred instances of drug shortages were recorded in the United States. A number of shortages have lasted over a year before reaching a solution.According to the FDA, manufacturing issues are indeed the main reason behind drug shortages. A single quality issue may affect several months of production plan.
Signs seen in the pharmaceutical sector indicate that there is a chronic problem with production capacities:
- There is a lack of alternative production sites for many crucial medications.
- Once one company has a production issue, other organizations in the supply chain do not have enough spare capacities.
- Hospitals regularly face the necessity to ration medications and adjust doses.
How Does a Pharmaceutical Manufacturing Partner Lessen That Risk
Selecting the proper partners in manufacturing can help resolve the problem. An experienced partner has a backup facility that can replace the original site in the case of its unexpected failure. The systems ensuring quality serve the function that is no less important.Having recorded and validated every stage of the process allows us to identify deviations.
The importance of identifying deviations cannot be overestimated since even the slightest alteration in the course of drug manufacturing can cause changes in the product. The partners that have many years of experience cooperate with regulators in various markets and know how to deal with inspections.
Moreover, a competent partner has acquired a network of facilities all round the globe. This provides a reliable base of flexible manufacturing partners that significantly reduces the chances of the occurrence of any failure.
What Will This Mean for Patients Going Forward
As practices in the area of medicine progress, the production and delivery processes surrounding pipeline drugs are growingly intricate. Innovating peptide therapies necessitate complicated production processes. Most of the times, these molecules require tens of synthesis steps to be completed.Patients rarely see all this process. However, it contributes greatly to their treatment outcomes. An uninterrupted supply of pipeline drugs assures timely treatment provision. It is especially important for patients suffering from chronic and psychological disorders as this results in better treatment results.
As the processes in this specialization develop further on, specialization in production resources will be of utmost importance due to its scarcity of replacement as well.
Where Does Neuland Fit into This Picture
The decisions made before the writing of the prescription also influence the success of the treatment. Moreover, a flexible supply chain can avoid the risk of events occurring which could take the patient away from the treatment process. Neuland Laboratories provides its customers with such flexibility. The company’s production capacity includes:- Three above cGMP-certified plants
- Approvals by the FDA, EMA and PMDA
- Technologies from small molecules to peptide APIs
FAQs
1. What is the distinction between a drug manufacturer and an API manufacturer?
A drug manufacturer produces the active ingredient in the product formulation. The drug producer is responsible for producing the final product in the form of tablets or capsules available in pharmacies and for patients. An API producer is responsible for the production of active pharmaceutical ingredients used in the medicines.2. How do pharmaceutical companies assess the quality of potential manufacturing partners?
Pharmaceutical companies assess potential manufacturing partners on the basis of:- The partner's compliance with regulatory requirements
- The capacity and backup level of production
- The quality management system and documentation
- The partner's experience in similar technologies
- On time completion of the project
3. Why is it important to have two sources of supply for essential medical products?
The dual sourcing system refers to the qualification of more than one manufacturer for a particular drug. This system greatly minimizes the risks borne by a single manufacturer. Thus, in case of malfunctioning of one manufacturer, supply for drugs may not be completely cut off.4. How much time is normally involved in qualifying a new manufacturer?
It usually takes several months or more than a year to qualify a new manufacturer depending on the complexity of the drug. Several stages which constitute the qualifying procedure are:- Initial facility audit
- Technology transfer
- Validation of the manufacturing process
- Regulatory experts’ review
- Production of initial batches
No comments:
Post a Comment
Please don't spam. Comments having links would not be published.